Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANX005 in ALS
NCT04569435Phase 2Completed
- Sponsor
- Annexon Biosciences
- Start
- Jan 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tanruprubart in amyotrophic lateral sclerosis (ALS), sponsored by Annexon Biosciences. Primary endpoint: Number of Participants Who Experienced Treatment-Emergent Adverse Events. Started Jan 2021; status: completed.
02
Drugs
tanruprubart
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04569435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04569435.